Next Article in Journal
Health Benefits of Resveratrol in Kidney Disease: Evidence from In Vitro and In Vivo Studies
Previous Article in Journal
Dietary Diversity of an Adult Solomon Islands Population
Open AccessArticle

Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study

1
Instituto de Neurobiología UNAM-Juriquilla, Querétaro 76230, Mexico
2
Hospital General Regional #1 IMSS, Querétaro 76000, Mexico
3
Clínica Hospital Dr. Ismael Vázquez Ortiz ISSSTE, Querétaro 76000, Mexico
*
Author to whom correspondence should be addressed.
Nutrients 2019, 11(7), 1623; https://doi.org/10.3390/nu11071623
Received: 20 June 2019 / Revised: 8 July 2019 / Accepted: 9 July 2019 / Published: 17 July 2019
This study analyzes an oral supplement of molecular iodine (I2), alone and in combination with the neoadjuvant therapy 5-fluorouracil/epirubicin/cyclophosphamide or taxotere/epirubicin (FEC/TE) in women with Early (stage II) and Advanced (stage III) breast cancer. In the Early group, 30 women were treated with I2 (5 mg/day) or placebo (colored water) for 7–35 days before surgery. For the Advanced group, 30 patients received I2 or placebo, along with FEC/TE treatment. After surgery, all patients received FEC/TE + I2 for 170 days. I2 supplementation showed a significant attenuation of the side effects and an absence of tumor chemoresistance. The control, I2, FEC/TE, and FEC/TE + I2 groups exhibited response rates of 0, 33%, 73%, and 100%, respectively, and a pathologic complete response of 18%, and 36% in the last two groups. Five-year disease-free survival rate was significantly higher in patients treated with the I2 supplement before and after surgery compared to those receiving the supplement only after surgery (82% versus 46%). I2-treated tumors exhibit less invasive potential, and significant increases in apoptosis, estrogen receptor expression, and immune cell infiltration. Transcriptomic analysis indicated activation of the antitumoral immune response. The results led us to register a phase III clinical trial to analyze chemotherapy + I2 treatment for advanced breast cancer. View Full-Text
Keywords: molecular iodine; breast cancer; chemoresistance; immune response; transcriptomic analysis molecular iodine; breast cancer; chemoresistance; immune response; transcriptomic analysis
Show Figures

Figure 1

MDPI and ACS Style

Moreno-Vega, A.; Vega-Riveroll, L.; Ayala, T.; Peralta, G.; Torres-Martel, J.M.; Rojas, J.; Mondragón, P.; Domínguez, A.; De Obaldía, R.; Avecilla-Guerrero, C.; Anguiano, B.; Delgado-González, E.; Zambrano-Estrada, X.; Cuenca-Micó, O.; De La Puente Flores, O.; Varela-Echavarría, A.; Aceves, C. Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study. Nutrients 2019, 11, 1623.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop